(Reuters) –
* Abbvie Expects Mid Teen percentage prescription volume growth for Humira: conf call
* Abbvie CEO says indirect biosimilar competition for Humira has been as expected in the quarter: conf call
* Abbvie expects 2016 revenue of about $26 billion : conf call
* Abbvie CEO says he remains confident in the IP protection on Humira: conf call
* Abbvie CEO says will consider opportunities that are complementary to their portfolio, but is no longer pursuing a big acquisition : conf calls Further company coverage: (Bengaluru Newsroom +1-646-223-8780).
Recent Articles on M&A
Source: Reuters.com
